Exosome Diagnostic and Therapeutic Global Market Report 2024

The exosome diagnostic and therapeutic market size has grown exponentially in recent years. It will grow from $0.36 billion in 2023 to $0.48 billion in 2024 at a compound annual growth rate (CAGR) of 31.1%. The growth observed in the historical period can be attributed to several key factors. These include significant advancements in biological research, the emergence and development of precision medicine approaches, innovations in biomedical imaging technologies, a strong focus on cancer research and advancements in oncology, and substantial investments made within the healthcare industry. These factors collectively contributed to the growth and progress witnessed during the historical period in the field of exosome diagnostics and therapeutics.

The exosome diagnostic and therapeutic market size is expected to see exponential growth in the next few years. It will grow to $1.28 billion in 2028 at a compound annual growth rate (CAGR) of 28.1%. The anticipated growth in the forecasted period can be attributed to several contributing factors. These include the increasing adoption of exosome-based clinical applications, the integration of exosomes with digital health technologies, a supportive regulatory environment fostering advancements, the rise of gene editing and RNA therapeutics furthering exosome research, and the expanded role of exosomes in immuno-oncology applications. Key trends expected in this forecasted period encompass the utilization of exosomes in drug discovery processes, innovative approaches in biomimetic exosome engineering, commercialization initiatives for exosome-based products, leveraging exosomes as carriers for therapeutic cargo, and the use of exosome-based liquid biopsy methods for cancer screening. These trends are projected to significantly influence and drive the growth of exosome diagnostics and therapeutics in the forecasted period.

The anticipated growth of the exosome diagnostic and therapeutic market is strongly driven by the increasing prevalence of chronic diseases. Chronic illnesses, lasting three months or more and prone to deterioration over time, are a significant health concern globally. Exosomes, utilized in both diagnostic and therapeutic capacities, emerge as promising biomarkers in cancer, enabling more sensitive disease monitoring and facilitating the accessibility of personalized medicine. In a projection from January 2023, the National Center for Biotechnology Information (NCBI) indicates a forecasted global count of 142.66 million individuals with chronic diseases by 2050. This statistic underscores the pivotal role played by the rising prevalence of chronic diseases in propelling the exosome diagnostics and therapeutics market.

The upward trajectory of the exosome diagnostic and therapeutic market is further fueled by the increasing size of the geriatric population. The term 'geriatric population' refers to individuals aged 65 years and older, often in the later stages of life. This demographic expansion contributes significantly to the demand for exosome diagnostics and therapeutics, as exosomes serve as valuable tools for diagnosing and addressing age-related conditions. Notably, a report from the World Health Organization (WHO) in October 2022 indicates a profound demographic shift, with one in six individuals projected to be 60 or older by 2030 globally. By 2050, an estimated 2.1 billion people worldwide will be 60 years old or older. This demographic shift underscores the substantial impact of the rising geriatric population on driving the growth of the exosome diagnostic and therapeutic market.

Major companies are actively engaged in developing innovative products, such as sample purification systems, to expand their customer base, boost sales, and drive revenue growth. A sample purification system encompasses a suite of processes and technologies designed to eliminate impurities and contaminants from various sample types, including DNA, RNA, proteins, and other biomolecules. As an illustration, in February 2023, Biological Dynamics Inc., a prominent US-based biotechnology company, introduced ExoVerita - an exosome-isolation platform designed for early disease surveillance and diverse applications. The ExoVita Pancreas assay, part of this platform, identifies specific exosomal protein indicators and has demonstrated the ability to detect Stage 1 and Stage 2 pancreatic ductal adenocarcinoma (PDAC) using blood-based exosome samples enriched on the patented ExoVerita apparatus. The company is actively validating these findings through the ExoLuminate registry trial (NCT05625529), recruiting high-risk PDAC patients to assess the clinical value of the test.

Major players in the exosome diagnostic and therapeutic market are adopting a strategic partnership approach to enhance the exosome purification process. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. A noteworthy example is the collaboration between Cytiva, a prominent US-based biotechnology company, and RoosterBio Inc., also a US-based biotechnology company. Announced in October 2023, this partnership aims to improve the exosome purification process, a current bottleneck hindering the widespread adoption of promising gene therapies and other innovative modalities. By combining the strengths of both entities, the collaboration seeks to address a significant challenge limiting the use of exosomes in therapeutic applications, particularly as carriers for gene therapies and biologics. The envisioned outcome is the advancement of large-scale manufacturing capabilities for exosomes.

In November 2021, Lonza Group AG, a renowned Switzerland-based company specializing in contract manufacturing and development solutions, successfully acquired an exosome manufacturing facility from Codiak BioSciences Inc. for a sum of $65 million. This strategic acquisition by Lonza is intended to broaden its scope of services, encompassing exosome assay and process development, analytics, and manufacturing services. Moreover, Lonza seeks to expedite advancements in exosome production, purification, and analytics through this acquisition. Codiak BioSciences Inc., a US-based clinical-stage biopharmaceutical company, is known for its expertise in developing exosome-based therapeutics.

Major companies operating in the exosome diagnostic and therapeutic market report are Thermo Fisher Scientific Inc., Lonza Group AG, Bio-Techne Corp., Miltenyi Biotec GmBH, Malvern Instruments Inc., BioVision Inc., System Biosciences LLC, Evox Therapeutics Ltd., ExCoBio Inc., BioCat GmbH, NanoSomix Inc. , Exosome Diagnostics Inc., Capricor Therapeutic Inc., Aethlon Medical Inc., Codiak BioSciences Inc., NX Pharmagen Inc., Exiqon A/S, Aegle Therapeutic Corporation, AMS Biotechnology Ltd., Cell Guidance Systems, Ciloa, Sienna Diagnostics, Sistemic Inc., Theoria Science, Mantra Bio Inc.

North America was the largest region in the exosome diagnostic and therapeutic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exosome diagnostic and therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the exosome diagnostic and therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary products within the exosome diagnostic and therapeutic market comprise instruments, software, reagents, and kits. Instruments refer to equipment utilized for precise and accurate execution of activities or experiments. These products find diverse applications in diagnostics and therapeutics and cater to various end-users, including academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, among others.

The exosome diagnostic and therapeutic market research report is one of a series of new reports that provides exosome diagnostic and therapeutic market statistics, including exosome diagnostic and therapeutic industry global market size, regional shares, competitors with an exosome diagnostic and therapeutic market share, detailed exosome diagnostic and therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the exosome diagnostic and therapeutic industry. This exosome diagnostic and therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The exosome diagnostic and therapeutic market consists of revenues earned by entities by providing services such as genomic sequencing, exome sequencing, resequencing, and targeted sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. The exosome diagnostic and therapeutic market also includes sales of exosome-based assays, exosome flow cytometry kits, and protein biomarker detection kits, which are used in providing exosome-based drug delivery services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.